Carmat
Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.
Carmat (ALCAR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.344x
Based on the latest financial reports, Carmat (ALCAR) has a cash flow conversion efficiency ratio of 0.344x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.58 Million) by net assets (€-51.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Carmat - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Carmat's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Carmat Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carmat ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BioNexus Gene Lab Corp Common stock
NASDAQ:BGLC
|
-0.181x |
|
PT Dewi Shri Farmindo Tbk
JK:DEWI
|
-0.032x |
|
Truong Long Engineering and Auto JSC
VN:HTL
|
N/A |
|
SEI
BK:SEI
|
0.240x |
|
TEMPUS RESOURCES LTD
F:4W0
|
N/A |
|
Hiper Global Ltd
TA:HIPR
|
0.127x |
|
Tissue Repair Ltd
AU:TRP
|
-0.091x |
|
Master Pack Group Bhd
KLSE:7029
|
0.097x |
Annual Cash Flow Conversion Efficiency for Carmat (2010–2024)
The table below shows the annual cash flow conversion efficiency of Carmat from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-51.13 Million | €-43.31 Million | 0.847x | -30.68% |
| 2023-12-31 | €-43.76 Million | €-53.48 Million | 1.222x | +104.05% |
| 2022-12-31 | €1.80 Million | €-54.38 Million | -30.175x | -788.21% |
| 2021-12-31 | €-13.72 Million | €-60.17 Million | 4.385x | +179.66% |
| 2020-12-31 | €7.82 Million | €-43.03 Million | -5.504x | -232.89% |
| 2019-12-31 | €24.34 Million | €-40.24 Million | -1.653x | +11.04% |
| 2018-12-31 | €20.54 Million | €-38.17 Million | -1.859x | -337.96% |
| 2017-12-31 | €57.21 Million | €-24.28 Million | -0.424x | +42.37% |
| 2016-12-31 | €28.89 Million | €-21.27 Million | -0.736x | +93.99% |
| 2015-12-31 | €1.40 Million | €-17.19 Million | -12.248x | -407.32% |
| 2014-12-31 | €7.76 Million | €-18.75 Million | -2.414x | -81.08% |
| 2013-12-31 | €7.23 Million | €-9.64 Million | -1.333x | +26.17% |
| 2012-12-31 | €9.94 Million | €-17.95 Million | -1.806x | -400.34% |
| 2011-12-31 | €26.89 Million | €-9.71 Million | -0.361x | +19.55% |
| 2010-12-31 | €15.49 Million | €-6.95 Million | -0.449x | -- |